Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome

Journal of Pathology

Volumn 214, Issue 1, 2008, Pages 10-16

  Rahner, N ^a   Friedrichs, N ^a   Steinke, V ^a   Aretz, S ^a   Friedl, W ^a   Buettner, R ^a   Mangold, E ^a   Propping, P ^a   Walldorf, C ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

COBRA; Colorectal cancer; HNPCC; Lynch syndrome; MLH1; Promoter methylation; SnaPshot

Indexed keywords

B RAF KINASE; PROTEIN MLH1;

ALLELE; ARTICLE; COLORECTAL CANCER; DNA METHYLATION; FAMILIAL CANCER; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GERM LINE; HUMAN; MICROSATELLITE INSTABILITY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; GERM-LINE MUTATION; HUMANS; MICROSATELLITE INSTABILITY; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS);

EID: 38049046496     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2263     Document Type: Article

References (27)

1. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348(10):919-932.
2. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999;116(6):1453-1456.
3. Aaltonen LA, Peltomaki P, Mecklin JP, Jarvinen H, Jass JR, Green JS, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994;54(7): 1645-1648.
4. Engel C, Forberg J, Holinski-Feder E, Pagenstecher C, Plaschke J, Kloor M, et al. Novel strategy for optimal sequential application of clinical criteria, immunohistochemistry and microsatellite analysis in the diagnosis of hereditary nonpolyposis colorectal cancer. Int J Cancer 2006;118(1):115-122.
5. Mangold E, Pagenstecher C, Friedl W, Mathiak M, Buettner R, Engel C, et al. Spectrum and frequencies of mutations in MSH2 and MLH1 identified in 1721 German families suspected of hereditary nonpolyposis colorectal cancer. Int J Cancer 2005;116(5):692-702.
6. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57(5):808-811.
7. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA 1998;95(12):6870- 6875.
8. Cunningham JM, Christensen ER, Tester DJ, Kim CY, Roche PC, Burgart LJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58(15):3455-3460.
9. Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352(18):1851-1860.
10. Yearsley M, Hampel H, Lehman A, Nakagawa H, de la Chapelle A, Frankel WL. Histologic features distinguish microsatellite-high from microsatellite-low and microsatellite-stable colorectal carcinomas, but do not differentiate germline mutations from methylation of the MLH1 promoter. Hum Pathol 2006;37(7):831-838.
11. Deng G, Peng E, Gum J, Terdiman J, Sleisenger M, Kim YS. Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. Br J Cancer 2002;86(4):574-579.
12. Nakagawa H, Nuovo GJ, Zervos EE, Martin EW Jr, Salovaara R, Aaltonen LA, et al. Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001;61(19):6991-6995.
13. Menigatti M, Di Gregorio C, Borghi F, Sala E, Scarselli A, Pedroni M, et al. Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes Cancer 2001;31(4):357-361.
14. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 1996;122(3):135-140.
15. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96(4):261-268.
16. Mathiak M, Rutten A, Mangold E, Fischer HP, Ruzicka T, Friedl W, et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am J Surg Pathol 2002;26(3):338-343.
17. Suter CM, Norrie M, Ku SL, Cheong KF, Tomlinson I, Ward RL. CpG island methylation is a common finding in colorectal cancer cell lines. Br J Cancer 2003;88(3):413-419.
18. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999;59(9):2029-2033.
19. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-954.
20. Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L, French AJ, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004;41(9):664-668.
21. Raedle J, Trojan J, Brieger A, Weber N, Schafer D, Plotz G, et al. Bethesda guidelines: relation to microsatellite instability and MLH1 promoter methylation in patients with colorectal cancer. Ann Intern Med 2001;135(8, Pt 1):566-576.
22. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001;10(26):3001-3007.
23. Kuismanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltomaki P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 2000;156(5):1773-1779.
24. Ollikainen M, Hannelius U, Lindgren CM, Abdel-Rahman WM, Kere J, Peltomaki P. Mechanisms of inactivation of MLH1 in hereditary nonpolyposis colorectal carcinoma: a novel approach. Oncogene 2007;26(31):4541-4549.
25. McGivern A, Wynter CV, Whitehall VL, Kambara T, Spring KJ, Walsh MD, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004;3(2):101-107.
26. Loughrey MB, Waring PM, Tan A, Trivett M, Kovalenko S, Beshay V, et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007;6(3):301-310.
27. Raevaara TE, Korhonen MK, Lohi H, Hampel H, Lynch E, Lonnqvist KE, et al. Functional significance and clinical phenotype of nontruncating mismatch repair variants of MLH1. Gastroenterology 2005;129(2):537-549.